ArticleAmerican journal on intellectual and developmental disabilities2026
Expressive Language Sample Concordance With ADOS-2 Scores: Autism, Down Syndrome, Fragile X Syndrome.
Article in American journal on intellectual and developmental disabilities, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Mazurek et al. (2019) put forth an Expressive Language (EL) score based on the Autism Diagnostic Observation Schedule, Second Edition Module administered and Item A1, establishing convergent validity with expressive language assessments for autism. The current study examines EL score relationships with transcribed language samples-including sensitivity to change-across 6- to 23-year-old individuals in three diagnostic groups: autism, Down syndrome, and Fragile X syndrome. Results demonstrate convergent validity of EL score with language complexity and lexical diversity, and variable patterns of divergence with talkativeness and nonverbal participation. In contrast to mean length of utterance in morphemes, EL score was not sensitive to 1-year change. These findings support the usefulness of EL score for quickly describing expressive language, but caution against its use as a clinical outcome or measure of change.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.